Firefly Neuroscience

Company Overview

Snapshot

Founded in January 2006 by Amir Geva, Firefly Neuroscience operates with 11–50 employees. The company has raised $82.59 million across 11 funding rounds from 8 investors. In May 2025, Firefly Neuroscience acquired Evoke Neuroscience, Inc., a medical device company, to expand its database, intellectual property, and commercial footprint.

Business overview

Firefly Neuroscience is a Health Tech & Life Sciences company focused on objective brain health assessment. The company develops Brain Network Analytics (BNA™) technology, an AI and advanced signal processing platform that records and compares brain function to an FDA-cleared, age-matched database. This technology enables clinicians and patients to make informed therapy and disease management decisions and track changes over time, primarily serving the digital healthcare, pharmaceuticals, and healthcare provider markets.

Strategic signal

In June 2026, Firefly Neuroscience's AI-Driven Evoke System powered the discovery of a novel electrophysiological biomarker for PTSD. This development is significant as it demonstrates the company's continued innovation in leveraging AI for critical neurological research and expands the potential applications of its technology, signaling strong growth potential in advanced diagnostic and therapeutic areas for investors.

Company Intelligence Q&A

What was the most recent significant product development for Firefly Neuroscience?

In June 2026, Firefly Neuroscience's AI-Driven Evoke System facilitated the discovery of a novel electrophysiological biomarker for PTSD, highlighting the platform's capability in advanced neurological research.

What was a key strategic partnership for Firefly Neuroscience in early 2025?

In February 2025, Firefly Neuroscience was accepted into the NVIDIA Connect program, providing the company with advanced software development resources and technical training to support its initiative of building a foundation model of the human brain using its FDA-cleared BNA™ technology.

What was a major acquisition by Firefly Neuroscience in 2025?

In May 2025, Firefly Neuroscience acquired Evoke Neuroscience, Inc. for $6 million, paid in cash and Firefly common stock. This acquisition significantly expanded Firefly's database, intellectual property, and commercial footprint, enhancing its proprietary foundation model of the human brain.

What was the outcome of Firefly Neuroscience's collaboration with Bright Minds Biosciences?

In October 2024, Firefly Neuroscience collaborated with. This validated the approach and set the stage for BMB-101 to advance to Phase 2.

What was a notable financial event for Firefly Neuroscience in late 2024?

In December 2024, Firefly Neuroscience closed a financing deal of up to $12.4 million, comprising $2.4 million in senior secured convertible notes and an equity line of credit for up to $10 million. These funds were allocated for growth and commercialization of its FDA-510(k) cleared Brain Network Analytics (BNA™) technology.